Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander

Manhal Izzy, Jae Oh, Kymberly D. Watt – 19 April 2018 – Cirrhotic cardiomyopathy in end‐stage liver disease is currently characterized by blunted contractile systolic response to stress with or without diastolic dysfunction in the absence of known heart disease. Since the establishment of the diagnostic criteria of cirrhotic cardiomyopathy in 2005, there have been multiple studies regarding its pathophysiology and pretransplant clinical course. The data regarding the post‐transplant course of this entity are sparse.

Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B

Shiu‐Feng Huang, Il‐Chi Chang, Chih‐Chen Hong, Tseng‐Chang Yen, Chao‐Long Chen, Cheng‐Chung Wu, Cheng‐Chung Tsai, Ming‐Chih Ho, Wei‐Chen Lee, Hsien‐Chung Yu, Ying‐Ying Shen, Hock‐Liew Eng, John Wang, Hui‐Hwa Tseng, Yung‐Ming Jeng, Chau‐Ting Yeh, Chi‐Ling Chen, Pei‐Jer Chen, Yun‐Fan Liaw – 18 April 2018 – Metabolic risk factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated with increased risk for nonviral hepatocellular carcinoma (HCC); however, few nonviral HCC studies have stratified patients according to underlying etiologies.

Subscribe to